NEW YORK, June 17, 2016 /PRNewswire/ --
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
On Thursday, shares in Parsippany, New Jersey headquartered specialty pharmaceutical Company, Allergan PLC, ended the session 0.77% lower at $237.29 with a total volume of 3.10 million shares traded. The Company's shares have advanced 4.27% in the last one month. The stock is trading 3.71% above its 50-day moving average. Moreover, shares of Allergan have a Relative Strength Index (RSI) of 50.14. Sign up and read the free notes on AGN at:
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The stock edged 0.69% higher to close the day at $45.05 with a total volume of 3.05 million shares traded. The Company's shares have advanced 9.82% in the last one month and 1.88% in the previous three months. The stock is trading 2.18% above its 50-day moving average. Additionally, Mylan's stock has an RSI of 53.19. The complimentary notes on MYL can be downloaded in PDF format at:
On Thursday, shares in Dublin, Ireland headquartered biopharmaceutical Company, Horizon Pharma PLC, ended the day 0.11% lower at $17.43 with a total volume of 2.12 million shares traded. Shares of the Company traded at a PE ratio of 210.00. The Company's shares have gained 14.82% in the last one month and 22.14% in the previous three months. The stock is trading above its 50-day moving average by 8.77%. Furthermore, shares of Horizon Pharma have an RSI of 56.85. Register for free on Stock-Callers.com and access the latest research on HZNP at:
Ewing, New Jersey headquartered clinical stage biopharmaceutical Company, Celator Pharmaceuticals Inc.'s stock finished Thursday's session 0.10% lower at $30.09 with a total volume of 1.24 million shares traded. Over the last one month and the previous three months, the Company's shares have surged 95.64% and 240.00%, respectively. Furthermore, the Company's stock has rallied 1,133.20% in the past one year. The stock is trading above its 50-day and 200-day moving averages by 61.52% and 354.11%, respectively. Celator Pharmaceuticals' stock has an RSI of 84.45. Get free access to your trade alert on CPXX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly at:
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
Phone number: +44-330-808-3765
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA